ライフサイエンスコーパス: taxane

1 nes, including a monoacetylated dioxygenated taxane.

2 er previously treated with trastuzumab and a taxane.

3 nfidence interval: -16%, -9.4%) after AC and taxane.

4 er previously treated with trastuzumab and a taxane.

5 a proposed biosimilar or trastuzumab plus a taxane.

6 4 mg/kg weekly and a further 80 to receive a taxane.

7 tigen (PSA) decline by cycle 4 (C4) switched taxane.

8 ar (n = 230) or trastuzumab (n = 228) with a taxane.

9 er previously treated with trastuzumab and a taxane.

10 C) who previously received trastuzumab and a taxane.

11 retherapy AR-V7-positive CTCs treated with a taxane.

12 ogen receptor signaling (ARS) inhibitor or a taxane.

13 onse and outcomes between ARS inhibitors and taxanes.

14 is associated with decreased sensitivity to taxanes.

15 t target microtubule disassembly, similar to taxanes.

16 neurotoxic effects of current agents such as taxanes.

17 with MBC pretreated with anthracyclines and taxanes.

18 of clinical benefit in patients treated with taxanes.

19 is commonly treated with anthracyclines and taxanes.

20 drogen receptor and the clinical efficacy of taxanes.

21 can affect in vivo tissue sensitivity toward taxanes.

22 to a variety of anticancer agents, including taxanes.

23 3RK inhibition may also sensitize cancers to taxanes.

24 sequential or combination anthracycline and taxane (106 patients in the scalp cooling group and 16 i

25 /= 30% PSA declines by C4 and did not switch taxane, 15 patients (24.6%) who did not achieve >/= 30%

26 Of patients switching taxane, 46.7% subsequently achieved >/= 50% PSA decrease

27 re essential for proper cellular response to taxanes, a widely used family of chemotherapeutic compou

28 These results indicate that taxanes act in CRPC patients at least in part by inhibit

29 se (pCR) from standard-of-care anthracycline/taxane (ACT) chemotherapy.

30 Anti-mitotic chemotherapeutic agents such as taxanes activate the spindle assembly checkpoint (SAC) t

31 lationship between BRCA1 (B1) expression and taxane activity remains unclear.

32 sitive disease, sequential anthracycline and taxanes administered concurrently with trastuzumab or do

33 ine into an adjuvant regimen that contains a taxane, an anthracycline, and cyclophosphamide improves

34 n for a planned access to minimally oxidized taxane analogues and a scalable laboratory preparation o

35 or the synergy observed when combinations of taxane and alternative site binding drugs are used.

36 with high probability of survival following taxane and anthracycline chemotherapy.

37 ated with chemotherapy containing sequential taxane and anthracycline-based regimens (then endocrine

38 In combination with taxanes and anthracyclines CDK4/6 inhibition and consequ

39 rone therapy, whereas in AR-V7-negative men, taxanes and enzalutamide or abiraterone may have compara

40 e transporters in the hepatic elimination of taxanes and indicate that this process can be inhibited

41 emical syntheses of eudesmanes, germacrenes, taxanes and ingenanes have all benefited from a strategy

42 inum agent, followed by later treatment with taxanes and irinotecan, provides some benefit.

43 who have received adjuvant chemotherapy with taxanes and platinum compounds.

44 l representative agents in clinical use, the taxanes and the vinca alkaloids, come from terrestrial s

45 cer, treated with anthracyclines followed by taxanes and trastuzumab were enrolled to be evaluated ev

46 Drugs such as taxanes and vinca alkaloids specifically target microtub

47 rotubule-targeting agents (MTA), such as the taxanes and vinca alkaloids, are used to treat a variety

48 e vs 78 [70%] of 111 patients treated with a taxane), and similar incidences of adverse events leadin

49 achieve >/= 30% PSA declines by C4 switched taxane, and 13 patients (21.3%) discontinued therapy bef

50 in to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete

51 previously treated with an anthracycline, a taxane, and capecitabine (and two to five previous regim

52 rdiotoxic effects (including anthracyclines, taxanes, and cyclophosphamide) were defined as time-depe

53 37-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which

54 h breast cancer treated with anthracyclines, taxanes, and trastuzumab, systolic longitudinal myocardi

55 cancer during treatment with anthracyclines, taxanes, and trastuzumab.

56 breast cancer receiving chemotherapy with a taxane, anthracycline, or both, those who underwent scal

57 , randomized, phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, la

58 Taxane antineoplastic agents are extensively taken up in

59 zumab and lapatinib (advanced setting) and a taxane (any setting) and with progression on two or more

60 In AR-V7-positive men, taxanes appear to be more efficacious than enzalutamide

61 ved the highest reported titer of oxygenated taxanes ( approximately 570 +/- 45 mg/L) in E. coli.

62 Taxanes are a key chemotherapy component for several mal

63 Taxanes are a standard of care therapy in castration-res

64 ently treated with hormone therapy, to which taxanes are added when the tumors become resistant to ca

65 The taxanes are effective microtubule-stabilizing chemothera

66 chanisms underlying the clinical activity of taxanes are poorly understood.

67 improve pCR, sequencing chemotherapy so that taxanes are received before anthracyclines could improve

68 Taxanes are the only chemotherapies used to treat patien

69 l utility of combining AURKA inhibitors with taxanes as a therapeutic strategy for the treatment of E

70 lly) on day 1 (except for patients receiving taxanes as part of moderately emetogenic chemotherapy, w

71 addition of gemcitabine to anthracycline and taxane-based adjuvant chemotherapy at this dose and sche

72 he Medicare cohort, 51% of patients received taxane-based and 32% received anthracycline-based chemot

73 Taxane-based anticancer treatments lead to the stabiliza

74 After 2005, a sharp increase in the use of taxane-based chemotherapy and a decline in anthracycline

75 of trastuzumab to adjuvant anthracycline and taxane-based chemotherapy does not result in long-term w

76 t cancer receiving neoadjuvant anthracycline-taxane-based chemotherapy in seven randomized trials wer

77 chieve a pCR after neoadjuvant anthracycline-taxane-based chemotherapy plus anti-HER2 treatment, even

78 Resistance to platinum- and taxane-based chemotherapy remains a major clinical imped

79 y) with placebo in women undergoing adjuvant taxane-based chemotherapy was conducted.

80 Younger age and taxane-based chemotherapy were associated with higher li

81 sion after primary surgery and platinum- and taxane-based chemotherapy were randomly assigned at a ra

82 ripheral neuropathy in patients treated with taxane-based chemotherapy.

83 nts with breast cancer are instead receiving taxane-based chemotherapy.

84 ts younger than 65 years were also receiving taxane-based chemotherapy.

85 with trastuzumab were more likely to receive taxane-based chemotherapy.

86 lation between Daxx and clinical response to taxane-based chemotherapy.

87 based chemotherapy and 64% (n = 91) received taxane-based chemotherapy.

88 Using a taxane-based radical trap that rearranges under Fe(PDP)

89 years were less likely to be treated with a taxane-based regimen, whereas patients who underwent 21-

90 oss of PI3K-C2alpha increases sensitivity to taxane-based therapy in pre-clinical models and in neoad

91 The variability in clinical efficacy of taxane-based therapy is likely a reflection of this vari

92 BC who had received prior anthracycline- and taxane-based therapy were randomly assigned to receive e

93 uzumab (in the context of anthracycline- and taxane-based therapy) continues to have a favorable bene

94 Anthracycline- and taxane-based three-drug chemotherapy regimens have prove

95 ateau has been reached in the development of taxane-based treatments for prostate cancer, this study

96 apy was classified as anthracycline-based or taxane-based, and the percentages of use were calculated

97 Receipt of a taxane before anthracycline was associated with improved

98 agent NACT with (n = 49) or without (n = 13) taxanes between 2008 and 2011.

99 ters of Canales et al. that characterize the taxane binding-site interaction between DCT and assemble

100 tic cell death, but recent data suggest that taxanes can also affect AR signaling.

101 expression status were randomly assigned to taxane/carboplatin (T/C) with or without cetuximab.

102 E To evaluate the efficacy of cetuximab plus taxane/carboplatin (TC) as first-line treatment of advan

103 ment of cancer cells with PI3K inhibitors or taxane causes FOXO1 localization in the nucleus, increas

104 Cabazitaxel is a second-line taxane chemotherapeutic agent that provides additional s

105 led patients with metastatic CRPC initiating taxane chemotherapy (docetaxel or cabazitaxel) at a sing

106 trastuzumab or lapatinib in combination with taxane chemotherapy (paclitaxel or docetaxel) for 24 wee

107 insight into therapeutic cross-resistance to taxane chemotherapy and androgen deprivation therapy in

108 frequently develop therapeutic resistance to taxane chemotherapy and antiandrogens.

109 ion chemotherapy followed by three cycles of taxane chemotherapy and then locoregional radiotherapy.

110 incorporated into a concurrent regimen with taxane chemotherapy as an important standard-of-care tre

111 ough the combination of surgery and platinum-taxane chemotherapy provide an effective treatment, drug

112 peripheral blood of CRPC patients receiving taxane chemotherapy revealed a significant correlation b

113 ABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adju

114 is not associated with primary resistance to taxane chemotherapy.

115 -resistant prostate cancer progressing after taxane chemotherapy.

116 atinib or the combination plus anthracycline-taxane chemotherapy.

117 ated with better OS in patients treated with taxane chemotherapy.

118 nt prostate cancer patients (CRPC) receiving taxane chemotherapy.

119 ers for the proper selection of patients for taxane chemotherapy.

120 patients might predict clinical responses to taxane chemotherapy.

121 Docetaxel is a chemotherapeutic agent of the taxane class of drugs for the treatment of breast cancer

122 49 compared TC6 with several standard AC and taxane combination regimens.

123 aggressive disease treated with platinum and taxane combination therapy.

124 eir ability to fit 24 data sets for platinum-taxane combinations and 21 data sets for various other c

125 Clinical outcomes were superior with taxanes compared with enzalutamide or abiraterone therap

126 Platinum and taxane compounds have demonstrated activity in uterine c

127 As representative members of taxanes containing five oxygen atoms, decinnamoyltaxinin

128 gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast

129 A metaanalysis of older trials comparing taxane-containing ICT to cisplatin and 5-fluorouracil is

130 llent performance status, anthracycline- and taxane-containing regimens are the standard of care.

131 The therapeutic efficacy of taxanes depends on whether slippage after SAC arrest cul

132 nduction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and fluorou

133 Of 4,554 patients who received at least one taxane dose, grade 2 to 4 neuropathy developed in 18%, 2

134 hat synchronized co-delivery of the platinum-taxane drug combination via single carrier to the same t

135 Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resist

136 s that clinical response was associated with taxane drug-target engagement, evidenced by decreased pe

137 Patients were re-exposed to taxanes either through desensitization, challenge, or re

138 llary nodes) to chemotherapy that included a taxane (either paclitaxel or docetaxel) at surgical rese

139 ainst microtubule stabilizing agents such as taxanes, epothilone B (EpoB) has merit, especially in co

140 xenobiotics, including cancer drugs, such as taxanes, epothilone B, and modulators of the estrogen pa

141 cal interest, including, but not limited to, taxanes, epothilones, statins, retinoids, di-/triterpene

142 eckpoint (SAC) to arrest anaphase onset, but taxane-exposed cells eventually undergo slippage to exit

143 Cabazitaxel, a novel taxane extended survival in men with progressive metasta

144 es cells to docetaxel, another member of the taxane family, and that STAT3 levels are significantly c

145 characteristic 6-8-6 tricyclic system of the taxane family, containing a bridgehead alkene, is forged

146 In patients who underwent both AC and taxane follow-up, the mean percentage of change from the

147 Trastuzumab, pertuzumab, and taxane for first-line treatment and T-DM1 for second-lin

148 Taxanes form a large family of terpenes comprising over

149 stuzumab or lapatinib, in combination with a taxane, from January 17, 2008, through December 1, 2011.

150 e [3%]), and neutropenia (three [3%]) in the taxane group.

151 a (43 [39%]), and anaemia (20 [18%]), in the taxane group.

152 ekly group and 15.4 months (9.2-18.1) in the taxane group.

153 ts with hypersensitivity reactions (HSRs) to taxanes has not been established.

154 ne; nab(R)-Paclitaxel), a novel solvent-free taxane, has demonstrated higher response rates and impro

155 for antimitotic chemotherapeutic drugs like taxanes, has implications for drug response and drug res

156 Anthracyclines and taxanes have been the standard neoadjuvant chemotherapie

157 or adjuvant trastuzumab, prior (neo)adjuvant taxane, hormone receptor status, and measurable disease

158 Chemotherapy with taxanes improves survival in patients with castrate resi

159 N: Trastuzumab emtansine was not superior to taxane in patients with previously treated, HER2-positiv

160 osimilar plus a taxane or trastuzumab plus a taxane in patients without prior treatment for ERBB2-pos

161 ansine 2.4 mg/kg weekly, and 37 to receive a taxane in the stage 1 part of the trial.

162 al inhibitors of SFK/Hck in combination with taxanes in a temporally constrained manner, where the ki

163 domized trials that investigated the role of taxanes in ICT, compared with surgery or CRT alone.

164 can help inform the choice between ARSI and taxanes in mCRPC patients.

165 e mechanisms of sensitivity or resistance to taxanes in men with chemotherapy-naive, metastatic, cast

166 been shown to improve outcomes when added to taxanes in patients with metastatic breast cancer.

167 Despite the initial efficacy of taxanes in treating CRPC, all patients ultimately fail d

168 osis in cancer cells, and shows synergy with taxanes in tumor models.

169 ression, and was highly synergistic with the taxanes in wild-type and drug-resistant DU145 cells.

170 hetic consortium produced 33 mg/L oxygenated taxanes, including a monoacetylated dioxygenated taxane.

171 Trials investigating taxane inclusion in induction chemotherapy and trials of

172 Taxanes induce microtubule stabilization, mitotic arrest

173 o aberrant MAPK activation and resistance to taxane-induced apoptosis.

174 In 26 CTC-evaluable patients, taxane-induced decrease in %ARNL (cycle 1 day 1 v cycle

175 acquired beta-tubulin mutations that prevent taxane-induced microtubule stabilization, confirming a r

176 cting splice variant ARv567 was sensitive to taxane-induced microtubule stabilization.

177 G1 in regulating slippage and the outcome of taxane-induced mitotic arrest, with potential implicatio

178 There was no association between taxane-induced neuropathy and outcome.

179 gle nucleotide polymorphisms associated with taxane-induced neuropathy.

180 Taxane-induced shifts in %ARNL may serve as an early bio

181 l modelling, here we show that exposure to a taxane induces phenotypic cell state transition towards

182 Here, we report that taxanes inhibit ligand-induced AR nuclear translocation

183 he nucleus to cooperate with tubulin towards taxane insensitivity.

184 2.4 mg/kg weekly) or physician's choice of a taxane (intravenous docetaxel 75 mg/m(2) every 3 weeks o

185 totoxic chemotherapy, especially platins and taxanes, is a widespread problem among cancer survivors

186 s [IC2/3]), chemotherapy type (vinflunine vs taxanes), liver metastases (yes vs no), and number of pr

187 Eribulin mesilate is a non-taxane microtubule dynamics inhibitor with a novel mode

188 who were receiving sequential anthracycline-taxane NACT between October 2008 and October 2012.

189 th the Food and Drug Administration-approved taxane nanoformulation (Abraxane).

190 uzumab administration with anthracycline and taxane neoadjuvant chemotherapy.

191 idates that might be used as alternatives to taxanes, on the basis of a published expression signatur

192 ere beginning neurotoxic chemotherapy with a taxane or platinum agent were recruited from oncology cl

193 Chemotherapy with a neurotoxic taxane or platinum agent.

194 of a proposed trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without

195 increased risk of FAEs in patients receiving taxanes or platinum agents (RR, 3.49; 95% CI, 1.82-6.66;

196 status, chemotherapy [with an anthracycline, taxane, or both], hormone receptor status [negative vs l

197 herapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment.

198 cancer patients treated with anthracyclines, taxanes, or fluoropyrimidines.

199 e treatment regimens include anthracyclines, taxanes, or fluoropyrimidines.Significance: These findin

200 at it is an endogenous resistance factor for taxanes, other natural product agents, and nucleoside an

201 ster derivatives (tetraalkoxysilanes) of the taxanes paclitaxel (PTX) and docetaxel (DTX) [i.e., PTX-

202 used by widely used chemotherapeutics in the taxane (paclitaxel), platinum-complex (oxaliplatin), and

203 ignment, investigators chose capecitabine, a taxane (paclitaxel, nab-paclitaxel, or docetaxel), gemci

204 The clinically and commercially successful taxanes, paclitaxel and docetaxel suffer from two major

205 nel lymph node biopsy, systemic therapy with taxanes, platinum agents, or dose-dense treatment can be

206 ere eligible if they had received first-line taxane/platinum-based combination chemotherapy and were

207 istant relapse-free survival after receiving taxane plus anthracycline neoadjuvant chemotherapy (MD A

208 (Nottingham-NeoACT; n=200), the MD Anderson taxane plus anthracycline-based neoadjuvant chemotherapy

209 plications may choose to avoid paclitaxel or taxane plus platinum combination therapies if other effi

210 t have been proposed for epothilone A in the taxane pocket of beta-tubulin.

211 S in patients with trastuzumab-resistant and taxane-pretreated, HER2-positive, advanced breast cancer

212 rubicin to create a sequential anthracycline-taxane regimen in early breast cancer.

213 the initial HSR and skin testing for guiding taxane reintroduction in patients with an HSR to these a

214 of the initial HSR and skin testing to guide taxane reintroduction is safe and allows a significant n

215 Data on 164 patients treated for a taxane-related HSR from April 2011 to August 2014 at the

216 ciated with survival showed superior OS with taxanes relative to ARS inhibitors when AR-V7-positive C

217 MR imaging-detectable effects of taxanes represent a combination of specific antimitotic

218 r understand the molecular basis of clinical taxane resistance as well as to identify individual pati

219 AT3 levels are significantly correlated with taxane resistance in lung cancer cell lines, suggesting

220 AT3 expression is a determinant of intrinsic taxane resistance in lung cancer.

221 nding the mechanisms underlying platinum and taxane resistance in ovarian cancer.

222 itoring of patients with BRCA2 mutations for taxane resistance is warranted.

223 The molecular basis of clinical taxane resistance remains poorly understood.

224 tion of IGF2 as a mechanism that can mediate taxane resistance through activation of IGF1/insulin rec

225 FOXM1 has been implicated in taxane resistance, but the molecular mechanism involved

226 ible to PTX-induced stabilization conferring taxane resistance.

227 owing that low B1 expression correlated with taxane resistance.

228 otubules and overcome multiple mechanisms of taxane resistance.

229 ibitor of LIMK may offer a strategy to treat taxane-resistant breast tumors and metastases.

230 may provide a therapeutic strategy to treat taxane-resistant cancers.

231 Telomere dynamics remained unchanged in taxane-resistant cells, which retained sensitivity to KM

232 an-aurora kinase inhibitor that is active in taxane-resistant tumor cell lines.

233 omeres and microtubules in taxane-sensitive, taxane-resistant, androgen-sensitive, and androgen-insen

234 on analysis of breast cancers indicates that taxane responses correlate positively with Myc and negat

235 apy regimens that combine anthracyclines and taxanes result in improved disease-free and overall surv

236 rastuzumab emtansine (2.4 mg/kg weekly) or a taxane (same regimen as above).

237 ctional Assessment of Cancer Therapy (FACT) -Taxane scale at 12 weeks.

238 y of targeting telomeres and microtubules in taxane-sensitive, taxane-resistant, androgen-sensitive,

239 e, whose expression has been correlated with taxane sensitivity in many solid tumors including non-sm

240 g ABCC10 functions as a major determinant of taxane sensitivity in mice.

241 r protein, thereby resulting in differential taxane sensitivity in vitro and in vivo.

242 n for the ability of BH3 mimetics to enhance taxane sensitivity.

243 ho had previously received trastuzumab and a taxane, separately or in combination, the first ADC to r

244 and laulimalide, drugs that bind outside the taxane site.

245 EM) reconstructions of MTs stabilized by the taxane-site binders Taxol and zampanolide, and by peloru

246 orters is strongly dependent on the selected taxane solubilizer.

247 ork necessary to access even higher oxidized taxanes such as 1 in a more practical fashion, thus empo

248 import that affect the antitumor efficacy of taxanes, suggesting a mechanistic rationale to customize

249 trial evaluated clinical benefit from early taxane switch and circulating tumor cell (CTC) biomarker

250 Conclusion The early taxane switch strategy was associated with improved PSA

251 ecitabine (Cape; 2,000 mg/m(2) for 14 days), taxane (Tax) -based (nab-paclitaxel 260 mg/m(2), docetax

252 ctivity of TC relative to AC regimens with a taxane (TaxAC) is unknown.

253 les a gram-scale preparation of the 'parent' taxane--taxadiene--which is the largest quantity of this

254 method here for two platinum compounds and a taxane that otherwise bound irreversibly to dialysis mem

255 This includes taxanes that are used routinely in clinics to treat pros

256 -positive metastatic breast cancer receiving taxanes, the use of a proposed trastuzumab biosimilar co

257 entify phase II and III trials that included taxane therapy from 1999 to 2011.

258 ding trastuzumab and lapatinib, and previous taxane therapy in any setting, were randomly assigned (i

259 Purpose Administration of anthracycline and taxane therapy in the adjuvant setting is considered a s

260 that is associated with superior survival on taxane therapy over ARS-directed therapy in a clinical p

261 180 HGS-OvCa patients treated with platinum-taxane therapy revealed 61 transcript isoforms that char

262 Patients were stratified by previous taxane therapy, visceral metastasis, hormone receptor st

263 breast carcinoma who had previously received taxane therapy.

264 nical trial population who received adjuvant taxane therapy.

265 elop resistance to standard of care platinum/taxane therapy.

266 tentially disabling complication of adjuvant taxane therapy.

267 uded because they were not initiating ARS or taxane therapy; and 18 were excluded for processing time

268 cal benefit achieved with solvent-based (sb) taxanes, these agents can be associated with significant

269 between the anthracycline-based regimen and taxane (third examination), and after all chemotherapy a

270 Adding taxanes to anthracycline-based adjuvant therapy improves

271 s exhibit potent combinatorial activity with taxanes to inhibit tumor growth.

272 eviously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine.

273 One of the striking physical features of taxane-treated cells is the localization of their microt

274 cells with stabilized microtubules, such as taxane-treated cells.

275 PSA PFS and PFS were significantly longer in taxane-treated men (HR, 0.19 [95% CI, 0.07-0.52] for PSA

276 tatistical plan required a sample size of 36 taxane-treated men.

277 Of 37 taxane-treated patients enrolled, 17 (46%) had detectabl

278 itive patients, PSA responses were higher in taxane-treated vs enzalutamide- or abiraterone-treated m

279 mg/kg weekly and 8.6 months (7.1-11.2) with taxane treatment (hazard ratio 1.15, 95% CI 0.87-1.51, o

280 The combination of RSPO3 inhibition and taxane treatment provides an approach to effectively tar

281 re the kinase inhibitor is administered post taxane treatment, but not when co-administered, markedly

282 riptional activity of ARv7 was unaffected by taxane treatment.

283 role in microtubule biology and response to taxane treatment.

284 continuation (31 [14%] vs 15 [14%]) than did taxane treatment.

285 ls and is associated with poorer response to taxane treatment.

286 ng response phenotypes for anthracycline and taxane, two common anticancer agents use in clinics.

287 d disease), including an anthracycline and a taxane, unless contraindicated.

288 terone or enzalutamide use ( P = .03), prior taxane use ( P = .02), and Eastern Cooperative Oncology

289 ine pain score of 4 to 6 v 7 to 10 and prior taxane use).

290 for the baseline score, osteoarthritis, and taxane use, adjusted 12-week BPI-SF scores did not diffe

291 prior abiraterone or enzalutamide use, prior taxane use, presence of visceral metastases, and Eastern

292 ase (MK-1775), KSP (ispinesib), and tubulin (taxanes, vinca alkaloids), are presented.

293 s (positive or negative) and treatment type (taxane vs enzalutamide or abiraterone).

294 Cabazitaxel, a next generation taxane, was the first Food and Drug Administration-appro

295 BC previously treated with anthracycline and taxanes were randomly assigned to ixabepilone (40 mg/m(2

296 thracycline-based regimen, with or without a taxane, were enrolled between May 2002 and March 2006.

297 after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged

298 d use of chemotherapeutic agents such as the taxanes, which cause severe gastrointestinal mucositis.

299 s was completely reversed in the presence of taxanes, which reconciles incompatible observations in c

300 that the in vitro and in vivo interaction of taxanes with OATP1B transporters is affected by the choi